UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

Clinical and experimental immunology, 2016-07, Vol.185 (1), p.61-71

2016

Volltextzugriff (PDF)

Anti‐CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis

Clinical and experimental immunology, 2013-12, Vol.174 (3), p.364-371

2013

Volltextzugriff (PDF)

Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-03, Vol.23 (2), p.198-206

2017

Volltextzugriff (PDF)

Medical Treatments in Patients with Primary Sclerosing Cholangitis Differ between Europe and North America

Journal of hepatology, 2016, Vol.64 (2), p.S641-S641

2016

Volltextzugriff (PDF)

Endogenous interleukin‐22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice

Clinical and experimental immunology, 2016-08, Vol.185 (2), p.154-164

2016

Volltextzugriff (PDF)

Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial

Journal of hepatology, 2017, Vol.66 (1), p.S73-S73

2017

Volltextzugriff (PDF)

Prospective validation of the Enhanced Liver Fibrosis test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis

Journal of hepatology, 2017, Vol.66 (1), p.S359-S359

2017

Volltextzugriff (PDF)

Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis

Journal of hepatology, 2017, Vol.66 (1), p.S360-S361

2017

Volltextzugriff (PDF)

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non‐European ancestry

HLA, 2017-10, Vol.90 (4), p.228-233

2017

Volltextzugriff (PDF)

Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis

Clinical and experimental immunology, 2015-06, Vol.180 (3), p.371-382

2015

Volltextzugriff (PDF)

Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis

Journal of hepatology, 2017, Vol.66 (1), p.S4-S5

2017

Volltextzugriff (PDF)

Serum fibroblast growth factor 19, 7α-Hydroxy-4-Cholesten-3-one, and bile acids and their associations with clinical characteristics in primary sclerosing cholangitis

Journal of hepatology, 2017, Vol.66 (1), p.S361-S361

2017

Volltextzugriff (PDF)

The immunobiology of primary sclerosing cholangitis

Autoimmunity reviews, 2005-03, Vol.4 (3), p.137-143

2005

Volltextzugriff (PDF)

Clarity: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Lopixibat Chloride (Formerly Lum001), a Novel Apical Sodium-Dependent Bile Acid Transporter Inhibitor, in the Treatment of Primary Biliary Cirrhosis Associated with Itching

Journal of hepatology, 2016, Vol.64 (2), p.S197-S197

2016

Volltextzugriff (PDF)

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

Gastroenterology (New York, N.Y. 1943), 2017-06, Vol.152 (8), p.1975-1984.e8

2017

Volltextzugriff (PDF)

DMT1 gene expression and cadmium absorption in human absorptive enterocytes

Toxicology letters, 2001-06, Vol.122 (2), p.171-177

2001

Volltextzugriff (PDF)

O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES – AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS

Journal of hepatology, 2014-04, Vol.60 (1), p.S525-S526

2014

Volltextzugriff (PDF)

Durable response in the markers of cholestasis through 18 months of open-label extension with obeticholic acid in primary biliary cholangitis

Digestive and liver disease, 2016-10, Vol.48, p.e236-e236

2016

Volltextzugriff (PDF)

694 LYSYL OXIDASE-LIKE 2 (LOXL2) PROTEIN IS INDUCED IN HUMAN CHOLESTATIC LIVER DISEASE AND IN ANIMAL MODELS OF CHOLANGIOPATHIES

Journal of hepatology, 2013-04, Vol.58, p.S281-S282

2013

Volltextzugriff (PDF)

Functional and molecular responses of human intestinal Caco-2 cells to iron treatment

The American journal of clinical nutrition, 2000-09, Vol.72 (3), p.770-775

2000

Volltextzugriff (PDF)

EPH84 Administrative Claims-Based Algorithm to Identify Patients with Primary Sclerosing Cholangitis

Value in health, 2023-06, Vol.26 (6), p.S179-S179

2023

Volltextzugriff (PDF)

EPH110 Structured Literature Review of Evidence on the Clinical, Humanistic, and Economic Burden of Primary Sclerosing Cholangitis

Value in health, 2023-06, Vol.26 (6), p.S184-S184

2023

Volltextzugriff (PDF)

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

Hepatology (Baltimore, Md.), 2023-02, Vol.77 (2), p.659-702

2023

Volltextzugriff (PDF)

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

The New England journal of medicine, 2011-03, Vol.364 (13), p.1195-1206

2011

Volltextzugriff (PDF)

1 – 25 von 216

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Englisch
(215)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

Anti‐CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis

Ledipasvir–sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders

Medical Treatments in Patients with Primary Sclerosing Cholangitis Differ between Europe and North America

Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

Endogenous interleukin‐22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice

Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial

Prospective validation of the Enhanced Liver Fibrosis test for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis

Prospective validation of serum alkaline phosphatase for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non‐European ancestry

Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis

Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis

Serum fibroblast growth factor 19, 7α-Hydroxy-4-Cholesten-3-one, and bile acids and their associations with clinical characteristics in primary sclerosing cholangitis

The immunobiology of primary sclerosing cholangitis

Clarity: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Lopixibat Chloride (Formerly Lum001), a Novel Apical Sodium-Dependent Bile Acid Transporter Inhibitor, in the Treatment of Primary Biliary Cirrhosis Associated with Itching

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

DMT1 gene expression and cadmium absorption in human absorptive enterocytes

O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES – AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS

Durable response in the markers of cholestasis through 18 months of open-label extension with obeticholic acid in primary biliary cholangitis

694 LYSYL OXIDASE-LIKE 2 (LOXL2) PROTEIN IS INDUCED IN HUMAN CHOLESTATIC LIVER DISEASE AND IN ANIMAL MODELS OF CHOLANGIOPATHIES

Functional and molecular responses of human intestinal Caco-2 cells to iron treatment

EPH84 Administrative Claims-Based Algorithm to Identify Patients with Primary Sclerosing Cholangitis

EPH110 Structured Literature Review of Evidence on the Clinical, Humanistic, and Economic Burden of Primary Sclerosing Cholangitis

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Suchergebnisse filtern